My research focus has been on the public health impact, risk factors, and treatments of the main causes of blindness in the developed and developing world: cataracts, glaucoma, and age-related macular degeneration. Since my last review, I have continued to publish on findings from the Ocular Hypertension Treatment Study (OHTS), the Incidence of Age-Related Macular Degeneration (IAMD), the Thessaloniki Eye Study (TES), and the Study of Osteoporotic Fractures- Eye Study (SOF-ES). In addition, I have begun investigating sources of visual impairment in children along with potential interventions (Scientific Paper #108 and Gerald Oppenheimer Family Foundation Center for Prevention of Eye Disease grant) as well as potential genetic risk factors for age-related macular degeneration (Scientific Paper #84 and American Health Assistance Foundation and National Eye Institute grants) and glaucoma (Gerald Oppenheimer Family Foundation Center for Prevention of Eye Disease grant). I reported that even for elderly women with age-related macular degeneration, quitting smoking can slow down the development of the late stages of the disease (Scientific Paper #95). I also guided a research effort showing that age-related macular degeneration impacts vision-specific quality of life in elderly women (Scientific Paper #101). In addition, with my co-authors, I have expanded the risk model for ocular hypertension to include mortality risk (Scientific Paper # 94) and have investigated when it is appropriate to treat glaucoma suspects (Scientific Paper #96). Another area of continued interest is the analysis and interpretation of data from a population-based study in Thessaloniki, Greece led by Fotis Topouzis, MD, who was a clinical and research fellow with me in 1997-1998. As the first large-scale, population-based study in Greece, TES has continued to provide a wealth of information regarding the prevalence of glaucoma, especially pseudoexfoliative glaucoma, in a Greek population (Scientific Papers # 90, 104 and 110). My clinical practice, which is focused primarily on glaucoma treatment, has provided me with numerous opportunities and collaborations to add to the clinical research literature on glaucoma (Scientific Papers # 78, 83, 93, 98, 103, 105, 107, and 109). Recent studies have reported on the adverse consequences of glaucoma surgeries (Scientific Papers #78, 83, 98 and 103) and potentially modifiable prognostic factors for the progression of glaucoma (Scientific Papers # 93, 105, and 109). In addition, a recent publication with my colleagues presents our work on a new way of detecting glaucomatous damage with visual field testing (Scientific Paper #107).
Anne L. Coleman, M.D., Ph.D. is the Fran and Ray Stark Professor of Ophthalmology at the Jules Stein Institute, David Geffen School of Medicine, UCLA, and Professor of Epidemiology at the UCLA Fielding School of Public Health. She is the Director for the UCLA Center for Eye Epidemiology, the Mobile Eye Clinic, and the Center for Community Ophthalmologists and Vision Health. She is a member of the U.S. Food and Drug Administration Ophthalmic Devices Panel, the U.S. Cochrane Collaboration Eyes and Vision Steering Group, the Board of Trustees of Helen Keller International and the ARVO Awards Committee. She is the Chair of the NEI’s National Eye Health Education Program Planning Committee, Director of the H. Dunbar Hoskins, Jr. M.D. Center for Quality Eye Care, executive editor of glaucoma for the American Journal of Ophthalmology, as well as the Secretary of Quality of Care for the American Academy of Ophthalmology. Her research is directed toward the diagnosis, treatment, and societal impact of visual impairment from uncorrected refractive error, glaucoma, cataracts, and age-related macular degeneration (AMD), including the study of lifestyle limitations imposed on patients with these kinds of eye diseases and disorders. She is a Co-Investigator for an NEI-funded study on immune response gene polymorphisms and AMD and a comparative effectiveness study on the treatment of open-angle glaucoma funded by the Agency for Healthcare Research and Quality (AHRQ). Clinical projects include a population-based study on the incidence of glaucoma and AMD in Thessaloniki, Greece; geographic variation in diagnostic and therapeutic procedures for eye diseases in the Medicare population; and prevention of visual impairment and blindness in school-aged children Dr. Coleman received her medical degree from the Medical College of Virginia where she earned membership in the Alpha Omega Alpha honor society. After a surgical internship at the Medical College of Virginia, she went to the University of Illinois of Chicago for her residency training in ophthalmology. She did a fellowship in Glaucoma at the Wilmer Eye Institute, Johns Hopkins University. She received a doctorate in Epidemiology from UCLA in 1997 and earned membership in the Delta Omega Honor Society.
Please check with the faculty member or their office about availability to serve during current academic period.
Coleman Anne L, Caprioli Joseph The logic behind target intraocular pressure.. American journal of ophthalmology. 2009; 147(3): 379-80.
Coleman Anne L The role of statistics in ophthalmology.. American journal of ophthalmology. 2009; 147(3): 387-8.
Seitzman Robin L, Mangione Carol, Ensrud Kristine E, Cauley Jane A, Stone Katie L, Cummings Steven R, Hochberg Marc C, Hillier Teresa A, Yu Fei, Coleman Anne L Postmenopausal hormone therapy and age-related maculopathy in older women.. Ophthalmic epidemiology. 2008; 15(5): 308-16.
Coleman Anne L, Miglior Stefano Risk factors for glaucoma onset and progression.. Survey of ophthalmology. 2008; 53 Suppl1(3): S3-10.
Roizen Alejandra, Ela-Dalman Noa, Velez Federico G, Coleman Anne L, Rosenbaum Arthur L Surgical treatment of strabismus secondary to glaucoma drainage device.. Archives of ophthalmology. 2008; 126(4): 480-6.